SC14D9C - Tourmaline Bio, Inc. (0001827506) (Subject)

SC TO-C - Tourmaline Bio, Inc. (0001827506) (Subject)

SC14D9C - Tourmaline Bio, Inc. (0001827506) (Subject)

8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

SCHEDULE 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

SCHEDULE 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

10-Q - Tourmaline Bio, Inc. (0001827506) (Filer)

8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

Chardan Capital Markets initiated coverage of Tourmaline with a rating of Buy and set a new price target of $70.00

Wedbush initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $42.00

BMO Capital Markets initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $50.00

H.C. Wainwright reiterated coverage of Tourmaline with a rating of Buy and set a new price target of $49.00 from $48.00 previously

Jefferies initiated coverage of Tourmaline with a rating of Buy and set a new price target of $41.00

H.C. Wainwright resumed coverage of Tourmaline with a rating of Buy and set a new price target of $48.00

Truist initiated coverage of Tourmaline with a rating of Buy and set a new price target of $43.00

Guggenheim initiated coverage of Tourmaline with a rating of Buy and set a new price target of $50.00

Piper Sandler initiated coverage of Tourmaline with a rating of Overweight and set a new price target of $65.00

– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline's pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases – – Transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions – NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines that establish new standards of care for patients with life-altering infla

  Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular diseasePacibekitug is a promising targeted therapy with the potential to reduce systemic inflammation—an independent and significant driver of cardiovascular risk—addressing a critical unmet need in ASCVD treatment Offer price of USD 48 per share valuing the company at approximately USD 1.4bn on a fully diluted basis Basel, September 9, 2025 – Novartis today announced that it has entered into an agreement to acquire Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a New York-based, publicly traded clinical-stage biopharmaceutica

– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary pharmacodynamic biomarkers of IL-6 pathway activity including lipoprotein(a), fibrinogen, and serum amyloid A – NEW YORK, Aug. 31, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases, today presented additional data from its ongoing Phase 2 TR

– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – — Additional data from the ongoing Phase 2 TRANQUILITY trial to be presented at the European Society of Cardiology Congress in August 2025 – – On track to initiate Phase 2 proof-of-concept trial in abdominal aortic aneurysm in the second half of 2025 – – Planning underway for a Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease – – Cash, cash equivalents, and investments of $256.4 million as of June 30, 2025, provide expected cash runw

– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – – Cardiovascular Scientific Advisory Board strengthened with recent appointments of Drs. Deepak L. Bhatt, Dipender Gill, Paul M. Ridker, and Tabassome Simon – – Cash, cash equivalents, and investments of $294.9 million as of December 31, 2024, providing expected cash runway into the second half of 2027 – NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transf

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: Leerink's Global Healthcare Conference 2025, MiamiFireside ChatTuesday, March 11, 2025, at 4:20 pm ET A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalineb

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: Guggenheim Securities SMID Cap Biotech Conference, New YorkFireside ChatWednesday, February 5, 2025, at 1:30 pm ET A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at i

– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – — Additional data from the ongoing Phase 2 TRANQUILITY trial to be presented at the European Society of Cardiology Congress in August 2025 – – On track to initiate Phase 2 proof-of-concept trial in abdominal aortic aneurysm in the second half of 2025 – – Planning underway for a Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease – – Cash, cash equivalents, and investments of $256.4 million as of June 30, 2025, provide expected cash runw

– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)

SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)

SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB). "We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of card

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa

NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board. "We are absolutely thrilled that Clay has joined Tourmaline as Chairman of the Board," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "Clay built Seagen into one of the largest independent biotech companies in the world by taking a therapeutic concept and developing from it multiple successful medicines